NR3C1 and post-traumatic stress disorder: In a pilot study, we reported that methylation of the NR3C1 exon 1 F promoter assessed at pretreatment, predicted treatment outcome, but was not significantly altered in responders or nonresponders to prolonged exposure, a cognitive behavioral therapy for PTSD [12].